每周股票复盘：祥生医疗（688358）取消监事会拟修订章程

Core Viewpoint - Xiangsheng Medical (688358) has experienced a decline in stock price and financial performance, indicating potential challenges in the medical device sector [1][4]. Stock Performance - As of August 29, 2025, Xiangsheng Medical's stock closed at 31.32 yuan, down 8.04% from the previous week [1]. - The stock reached a peak of 35.27 yuan on August 27, 2025, and a low of 30.96 yuan on August 29, 2025 [1]. - The company's current market capitalization is 3.512 billion yuan, ranking 102 out of 126 in the medical device sector and 4147 out of 5152 in the A-share market [1]. Shareholder Changes - As of June 30, 2025, the number of shareholders increased to 6,631, up by 122 from March 31, 2025, representing a growth of 1.87% [3][7]. - The average number of shares held per shareholder decreased from 17,200 shares to 16,900 shares, with an average holding value of 501,400 yuan [3]. Financial Performance - For the first half of 2025, Xiangsheng Medical reported a main revenue of 236 million yuan, a year-on-year decrease of 4.61% [4][7]. - The net profit attributable to shareholders was 69.696 million yuan, down 14.32% year-on-year [4][7]. - The second quarter of 2025 saw a main revenue of 108 million yuan, an increase of 1.37% year-on-year, but the net profit decreased by 21.57% to 28.0818 million yuan [4]. Company Announcements - The company plans to abolish the supervisory board, transferring its powers to the audit committee of the board of directors, pending approval at the 2025 first extraordinary general meeting [5][7]. - The company reported a net fundraising amount of 919 million yuan from its initial public offering, with 743 million yuan invested in projects by June 30, 2025 [5]. - Research and development expenses for the first half of 2025 amounted to 37.6131 million yuan, representing 15.93% of revenue, with R&D personnel accounting for 34.3% of the workforce [5]. - The company has signed an agreement with the Gates Foundation to jointly develop innovative obstetric and breast ultrasound equipment [5].